Abstract:Christoph U Correll, 1–3 Nina R Schooler 4 1 The Zucker Hillside Hospital, Division of Psychiatry Research, Northwell Health, Glen Oaks, NY, USA; 2 The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Department of Psychiatry and Molecular Medicine, New York, NY, USA; 3 Charité Universitätsmedizin, Department of Child and Adolescent Psychiatry, Berlin, Germany; 4 State University of New York, Downstate Medical Center, Brooklyn, NY, USA Correspondence: Christoph U Correll The Zucker Hillside Hospital, Division of Psychiatry Research, 75-59 263rd Street, Glen Oaks, NY 11004, USA Tel +1 718 470-4812 Email ccorrell@northwell.edu Schizophrenia is frequently a chronic and disabling disorder, characterized by heterogeneous positive and negative symptom constellations. The objective of this review was to provide information that may be useful for clinicians treating patients with negative symptoms of schizophrenia. Negative symptoms are a core component of schizophrenia that account for a large part of the long-term disability and poor functional outcomes in patients with the disorder. The term negative symptoms describes a lessening or absence of normal behaviors and functions related to motivation and interest, or verbal/emotional expression. The negative symptom domain consists of five key constructs: blunted affect, alogia (reduction in quantity of words spoken), avolition (reduced goal-directed activity due to decreased motivation), asociality, and anhedonia (reduced experience of pleasure). Negative symptoms are common in schizophrenia; up to 60% of patients may have prominent clinically relevant negative symptoms that require treatment. Negative symptoms can occur at any point in the course of illness, although they are reported as the most common first symptom of schizophrenia. Negative symptoms can be primary symptoms, which are intrinsic to the underlying pathophysiology of schizophrenia, or secondary symptoms that are related to psychiatric or medical comorbidities, adverse effects of treatment, or environmental factors. While secondary negative symptoms can improve as a consequence of treatment to improve symptoms in other domains (ie, positive symptoms, depressive symptoms or extrapyramidal symptoms), primary negative symptoms generally do not respond well to currently available antipsychotic treatment with dopamine D 2 antagonists or partial D 2 agonists. Since some patients may lack insight about the presence of negative symptoms, these are generally not the reason that patients seek clinical care, and clinicians should be especially vigilant for their presence. Negative symptoms clearly constitute an unmet medical need in schizophrenia, and new and effective treatments are urgently needed. Keywords: schizophrenia, negative symptoms, prevalence, clinical presentation, diagnosis, treatment

Histamine H1 Receptor in Basal Forebrain Cholinergic Circuit: A Novel Target for the Negative Symptoms of Schizophrenia?

Histamine H 1 Receptor Deletion in Cholinergic Neurons Induces Sensorimotor Gating Ability Deficit and Social Impairments in Mice

Histamine H1 receptor deletion in cholinergic neurons induces sensorimotor gating ability deficit and social impairments in mice

Deficiency of H1 receptor in cholinergic neurons selectively leads to schizophrenia-like negative symptoms

A Study of Fractional Amplitude of Low Frequency Fluctuation in Schizophrenia Patients with Persistent Verbal Auditory Hallucinations

Relationship Between Negative Symptoms and Neurocognitive Functions in Adolescent and Adult Patients with First-Episode Schizophrenia

Histamine H2 receptor deficit in glutamatergic neurons contributes to the pathogenesis of schizophrenia

Histamine H <sub>2</sub> receptor deficit in glutamatergic neurons contributes to the pathogenesis of schizophrenia

Distinguishing Hypochondriasis and Schizophrenia Using Regional Homogeneity: a Resting-State Fmri Study and Support Vector Machine Analysis.

Histamine and histamine receptors: Roles in major depressive disorder

The Histaminergic System in Neuropsychiatric Disorders

Frontal white matter abnormalities reveal the pathological basis underlying negative symptoms in antipsychotic-naïve, first-episode patients with adolescent-onset schizophrenia: Evidence from multimodal brain imaging

Metabolite differences in the medial prefrontal cortex in schizophrenia patients with and without persistent auditory verbal hallucinations: a <SUP>1</SUP>H MRS study

Frontostriatal Circuitry and the Tryptophan Kynurenine Pathway in Major Psychiatric Disorders

Histamine-3 receptor availability and glutamate levels in the brain: a PET-1H-MRS study of patients with schizophrenia and healthy controls

Metabolite differences in the medial prefrontal cortex in schizophrenia patients with and without persistent auditory verbal hallucinations: a 1 H MRS study

A Selective Review of the Excitatory-Inhibitory Imbalance in Schizophrenia: Underlying Biology, Genetics, Microcircuits, and Symptoms

Emerging 5-HT receptor antagonists for the treatment of Schizophrenia

Revisiting Preclinical Observations of Several Histamine H3 Receptor Antagonists/Inverse Agonists in Cognitive Impairment, Anxiety, Depression, and Sleep–Wake Cycle Disorder

Suppression of Excitatory Synaptic Transmission in the Centrolateral Amygdala Via Presynaptic Histamine H3 Heteroreceptors

Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment